REFERENCES
- Teeters V W, Bird A C. The development of neovascularization of senile disciform macular degeneration. Am J Ophthalmol. 1973; 76(1)1–18, [INFOTRIEVE], [CSA]
- Holz F G, Pauleikhoff D, Klein R, et al. Pathogenesis of lesions in late age-related macular disease. Am J Ophthalmol. 2004; 137(3)504–510, [INFOTRIEVE], [CSA], [CROSSREF]
- Grossniklaus H E, Green W R. Choroidal neovascularization. Am J Ophthalmol. 2004; 137(3)496–503, [INFOTRIEVE], [CSA], [CROSSREF]
- Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: Two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2001; 131(5)541–560, [CSA], [CROSSREF]
- Jonas J B, et al. Intravitreal triamcinolone acetonide for exudative age related macular degeneration. Br J Ophthalmol. 2003; 87(4)462–468, [INFOTRIEVE], [CSA], [CROSSREF]
- Danis R P, et al. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000; 20(3)244–250, [INFOTRIEVE], [CSA], [CROSSREF]
- Gragoudas E S, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004; 351(27)2805–2816, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: Phase II study results. Ophthalmology 2003; 110(5)979–986, [CSA], [CROSSREF]
- D'Amico D J, et al. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: Twelve-month clinical outcomes. Ophthalmology 2003; 110(12)2372–2383, discussin 2384–2385[INFOTRIEVE], [CSA], [CROSSREF]
- Gaudreault J, et al. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005; 46(2)726–733, [INFOTRIEVE], [CSA], [CROSSREF]
- Fairman M P. DNA polymerase delta/PCNA: Actions and interactions. J Cell Sci. 1990; 95(Pt 1)1–4, [INFOTRIEVE], [CSA]
- Liu Y C, et al. Requirement for proliferating cell nuclear antigen expression during stages of the Chinese hamster ovary cell cycle. Biochemistry 1989; 28(7)2967–2974, [INFOTRIEVE], [CSA], [CROSSREF]
- Maga G, Hubscher U. Proliferating cell nuclear antigen (PCNA): A dancer with many partners. J Cell Sci. 2003; 116(Pt 15)3051–3060, [INFOTRIEVE], [CSA], [CROSSREF]
- Mandava N, et al. Ribozyme to proliferating cell nuclear antigen to treat proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 2002; 43(10)3338–3348, [INFOTRIEVE], [CSA]
- Taylor N R, et al. Chimeric DNA-RNA hammerhead ribozymes have enhanced in vitro catalytic efficiency and increased stability in vivo. Nucleic Acids Res. 1992; 20(17)4559–4565, [INFOTRIEVE], [CSA]
- Frimerman A, et al. Chimeric DNA-RNA hammerhead ribozyme to proliferating cell nuclear antigen reduces stent-induced stenosis in a porcine coronary model. Circulation 1999; 99(5)697–703, [INFOTRIEVE], [CSA]
- Blumenkranz M, et al. 5-fluorouracil: New applications in complicated retinal detachment for an established antimetabolite. Ophthalmology 1984; 91(2)122–130, [INFOTRIEVE], [CSA]
- Blumenkranz M S, et al. Fluorouracil for the treatment of massive periretinal proliferation. Am J Ophthalmol. 1982; 94(4)458–467, [INFOTRIEVE], [CSA]
- Binder S, et al. Inhibition of experimental intraocular proliferation with intravitreal 5-fluouracil. Graefes Arch Clin Exp Ophthalmol. 1983; 221(3)126–129, [CSA]
- Peyman G A, Schulman J. Proliferative vitreoretinopathy and chemotherapeutic agents. Surv Ophthalmol. 1985; 29(6)434–442, [INFOTRIEVE], [CSA], [CROSSREF]
- Leon J A, et al. Effects of fluorouracil and fluorouridine on protein synthesis in rabbit retina. Invest Ophthalmol Vis Sci. 1990; 31(9)1709–1716, [INFOTRIEVE], [CSA]
- Barrada A, et al. Evaluation of intravitreal 5-fluorouracil, vincristine, VP 16, doxorubicin, and thiotepa in primate eyes. Ophthalmic Surg. 1984; 15(9)767–769, [INFOTRIEVE], [CSA]
- Stern W H, et al. Ocular toxicity of fluorouracil after vitrectomy. Am J Ophthalmol. 1983; 96(1)43–51, [INFOTRIEVE], [CSA]
- Cai J, et al. Cytotoxic effects of antiproliferative agents on human retinal glial cells in vitro. Int Ophthalmol 2001; 24(4)225–231, [INFOTRIEVE], [CSA], [CROSSREF]
- Kulnig W, et al. Inhibition of experimental intraocular proliferation with intravitreous 5-fluouracil. A transmission electron-microscopic study in rabbits. Ophthalmologica. 1984; 188(4)248–258, [INFOTRIEVE], [CSA]
- Borhani H, et al. Suppression of experimental proliferative vitreoretinopathy by sustained intraocular delivery of 5-FU. Int Ophthalmol. 1995; 19(1)43–49, [INFOTRIEVE], [CSA], [CROSSREF]
- Cheng L, et al. Efficient gene transfer to retinal pigment epithelium cells with long-term expression. Retina 2005; 25(2)193–201, [INFOTRIEVE], [CSA], [CROSSREF]
- El Bradey M, et al. Preventive versus treatment effect of AG3340, a potent matrix metalloproteinase inhibitor in a rat model of choroidal neovascularization. J Ocul Pharmacol Ther. 2004; 20(3)217–236, [INFOTRIEVE], [CSA], [CROSSREF]
- Case J L, et al. Clearance of intravitreal 3H-fluorouracil. Ophthalmic Surg. 1985; 16(6)378–381, [INFOTRIEVE], [CSA]